NasdaqHealth CareHealth Care SuppliesS&P SmallCap 600
$172.11
+4.46 (+2.66%)
Close of Nov 06, 2026 · end-of-day data
ICUI 8-K filings in 2026
Every material Form 8-K ICU Medical filed with the SEC in 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
ICU Medical reported third quarter 2026 GAAP revenue of $560.4 million, up from $537.0 million a year earlier, and GAAP net income of $26.8 million, or $1.07 per diluted share, compared with a net loss of $3.4 million in the prior-year quarter. The company reaffirmed its full-year 2026 guidance and now expects to finish toward the higher end of the range, which matters to shareholders because it signals the company expects its annual results to land near the top of its prior outlook.
Q3 2026 GAAP revenue $560.4 million vs. $537.0 million in Q3 2025; GAAP gross margin 42% vs. 37%
Q3 2026 adjusted diluted EPS $2.44 vs. $2.03 in Q3 2025; adjusted EBITDA $113.9 million vs. $105.9 million
Full-year 2026 guidance reaffirmed: GAAP net income $73 million to $83 million, adjusted EBITDA $415 million to $435 million, adjusted diluted EPS $8.60 to $9.00
Company expects to end fiscal 2026 toward the higher end of the guidance range; results released November 5, 2026
ICU Medical reported second quarter 2026 GAAP revenue of $551.7 million, up 1% from a year earlier, and adjusted diluted earnings per share of $2.37, up from $2.10. GAAP net income fell to $19.1 million from $35.3 million, a year-over-year comparison that includes a $41.8 million gain on the 2025 sale of the IV Solutions business. The company raised its fiscal 2026 guidance, including adjusted EBITDA of $415 million to $435 million and adjusted diluted EPS of $8.60 to $9.00.
Q2 2026 GAAP revenue was $551.7 million, up 1%; organic revenue, excluding the IV Solutions divestiture and currency, rose 6%.
Q2 2026 GAAP diluted EPS was $0.76, versus $1.43 a year earlier, when results included a $41.8 million gain on sale of business.
Adjusted EBITDA was $110.0 million, compared with $100.3 million in Q2 2025.
Fiscal 2026 guidance: GAAP net income raised to $73 million to $83 million from $26 million to $44 million; adjusted diluted EPS raised to $8.60 to $9.00 from $7.75 to $8.45.
ICU Medical reported first quarter 2026 results on May 7, 2026. GAAP revenue fell 12% year over year to $530.2 million, mainly due to the May 1, 2025 divestiture of its IV Solutions business, while GAAP net income swung to $30.1 million from a $15.5 million loss, helped by a $33.4 million tax benefit. The filing does not include new full-year guidance, and adjusted EBITDA was roughly flat at $98.7 million.
GAAP revenue was $530.2 million, down from $604.7 million; non-GAAP organic revenue rose 1% excluding the IV Solutions divestiture and foreign currency.
GAAP net income was $30.1 million, or $1.20 per diluted share, versus a net loss of $15.5 million, or $0.63 per share, a year earlier.
Adjusted diluted EPS was $1.97, up from $1.72; adjusted EBITDA was $98.7 million, versus $99.4 million.
Free cash flow was $27.6 million, down from $36.7 million, and cash and cash equivalents were $288.3 million at March 31, 2026.
ICU Medical's Compensation Committee approved an amendment to its Executive Severance Plan on February 20, 2026, extending the plan's expiration date by three years to December 31, 2028. The change is effective as of December 31, 2025, and the full amendment is filed as Exhibit 10.1.
Compensation Committee approved the amendment to the Executive Severance Plan on February 20, 2026
Amendment extends the plan's expiration date by three years, to December 31, 2028
Change is effective as of December 31, 2025; full text filed as Exhibit 10.1
ICU Medical reported fourth quarter 2025 revenue of $540.7 million, down from $629.8 million a year earlier, and a GAAP net loss of $15.7 million, smaller than the prior-year loss of $23.8 million. Adjusted diluted EPS fell to $1.91 from $2.11, and adjusted EBITDA fell to $98.2 million from $105.5 million. The company also issued fiscal 2026 guidance of GAAP net income of $26 million to $44 million and adjusted EPS of $7.75 to $8.45.
Q4 2025 revenue was $540.7 million versus $629.8 million in Q4 2024; Vital Care fell $110.3 million after the IV Solutions business was disposed of on May 1, 2025
GAAP net loss was $(15.7) million, or $(0.64) per diluted share, versus $(23.8) million, or $(0.97), a year earlier
Adjusted diluted EPS was $1.91 versus $2.11; adjusted EBITDA was $98.2 million versus $105.5 million
Fiscal 2026 guidance: GAAP net income of $26 million to $44 million; adjusted EBITDA of $400 million to $430 million; adjusted EPS of $7.75 to $8.45
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every ICU Medical filing is on SEC EDGAR ↗. 8-K briefs of other companies →